Media headlines about Grifols SA, Barcelona (NASDAQ:GRFS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Grifols SA, Barcelona earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.008799225392 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Grifols SA, Barcelona (NASDAQ:GRFS) traded up $0.23 during mid-day trading on Monday, reaching $22.41. The company’s stock had a trading volume of 311,014 shares, compared to its average volume of 618,066. The company has a market cap of $5,860.00, a PE ratio of 24.10, a PEG ratio of 1.66 and a beta of 1.02. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17. Grifols SA, Barcelona has a 52-week low of $15.74 and a 52-week high of $24.20.

GRFS has been the subject of a number of recent analyst reports. Citigroup initiated coverage on shares of Grifols SA, Barcelona in a research report on Tuesday, October 31st. They issued a “buy” rating for the company. Zacks Investment Research cut shares of Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. UBS Group cut shares of Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research report on Friday, November 24th. Finally, BidaskClub upgraded shares of Grifols SA, Barcelona from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $24.00.

COPYRIGHT VIOLATION WARNING: “Grifols SA, Barcelona (GRFS) Receiving Somewhat Positive Media Coverage, Report Shows” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://theolympiareport.com/2017/12/25/grifols-sa-barcelona-grfs-receiving-somewhat-positive-media-coverage-report-shows.html.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Insider Buying and Selling by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with Analyst Ratings Network's FREE daily email newsletter.